Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Anju Ghangurde

Anju Ghangurde is Scrip's Deputy Asia Editor and has about two decades of experience in journalism including stints at India's mainstream financial dailies -The Economic Times, The Hindu Business Line and The Financial Express.  She covers a broad range of issues including competition and collaboration between generics and innovator firms, drug pricing and the evolving regulatory and legal framework in the region. She is also a recipient of the British Chevening Scholarship for Young Indian Journalists (2000-01) awarded by the Foreign & Commonwealth Office.
Set Alert for Articles By Anju Ghangurde

Latest From Anju Ghangurde

Content Personalization Scores As Pharma Ups Digital Ante

Pharma’s digital spend is expected to spurt in the coming years and firms are deploying a range of initiatives to deliver personalized content to physicians via preferred channels. KOL webinars feature among the top three approaches for marketers across the Americas, Europe and Asia, a new survey shows.

Commercial Strategy

Monroe Site Commercialization ‘Critical’ For Glenmark’s US Step-Up

Glenmark expects its first US manufacturing site to go commercial next year, accelerating growth in that market, while it sets right certain compliance blips back home. The Indian firm is also on course to divest certain non-core assets but notes that bringing in a minority partner for its API unit is not a priority.

Commercial Sales & Earnings

Aurobindo Integrates Apotex And Prepares For Sandoz

Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.

Sales & Earnings Strategy

Aurobindo Says Nothing ‘Extraneous’ Holding Up FTC Nod For Sandoz Deal

Aurobindo believes it has “substantially addressed” all requirements for an FTC go-ahead for its acquisition of Sandoz’s US dermatology and generic oral solids businesses. The integration of the acquired Apotex business in Europe is also shaping up.

Commercial Sales & Earnings

Ex-Sun Employee Alleges Reprisal For Opposing US Off-Label Practices

A Sun Pharma executive dismissed earlier this year has claimed retaliation by the company after she objected to the Indian firm’s alleged off-label marketing practices. Sun refutes the allegations and vows to vigorously defend itself, while experts suggest a settlement may be the way forward.

Regulation Legal Issues

Six Questions For TB Alliance CEO On Pretomanid And Pricing Issues

TB Alliance CEO Mel Spigelman outlines to Scrip the contours of the non-profit’s commercialization deal with Mylan for pretomanid, which is part of an oral combination regimen, and maintains that the $1/day pricing ask for the drug is based on flawed assumptions and not currently feasible.

Commercial Strategy
See All
UsernamePublicRestriction

Register